SightCall Partners with Lavazza Group, Uses AR Visual Assistance for Rapid Remote Maintenance
SightCall, the world’s leading augmented reality (AR)-powered visual assistance platform, today announced its partnership with Italy’s Lavazza Group to offer AR-powered remote visual assistance for customer care and maintenance of its coffee machines. One of the world’s most important coffee roasters and a global enterprise with products and distributors in more than 140 countries, Lavazza Group is accelerating its use of virtual assistance technologies to support the ongoing expansion of its product portfolio and continued efforts to become more responsive to fast-changing consumer needs.
“We are proud to partner with Lavazza Group to provide global service solutions for easier and faster product maintenance and repair,” said Thomas Cottereau, founder and CEO of SightCall. “Now more than ever, the world’s top brands are turning to digital support that allows them to provide issue resolution with minimal service disruption. SightCall will enable Lavazza to work through customer care issues immediately, maintaining their hard-earned reputation for high-quality coffee products.”
SightCall provides the company with a comprehensive visual support tool for customer service agents to guide customers to troubleshoot issues, such as descaling coffee machines or basic accessory maintenance remotely. The AR interface lets remote agents draw, point and highlight onto the customer’s smartphone, and high-definition picture assures the highest call qualities even in low-bandwidth environments. Device-agnostic, SightCall performs on a range of user products from smartphones and tables to specialist equipment such as smart glasses.
Lavazza Group, with more than 4,000 employees and revenues of more than EUR 2 billion (2020 Financial Statement), switched to SightCall from a previous visual assistance provider. This decision stemmed from its desire to move from a local approach to a global template offering maximum portability and seamless CRM integration, reinforced by strong GDPR compliance.
Lavazza first piloted SightCall with its customer service teams in France and Germany in the middle of the COVID-19 lockdown in April. Customer support teams were impressed by the ease of use and the level of confidence quickly developed with the tool, providing them with good insight into how a long-term partnership would work.
The company has plans to scale up usage to 130+ customer support agents in seven countries over the next three years. The company plans to cover multiple regions of the world where it provides products, bolstered by the SightCall app’s ability to operate in 13 different languages. Lavazza will also increase the number of codes and use cases it applies SightCall to, with more readily available data from its CRM and responses to SightCall customer surveys telling it where visual assistance can best be deployed to resolve maintenance issues.
“Everywhere our coffee is consumed, Lavazza innovates to enhance the experiences of our customers and consumers, providing fast and accessible service when and where they need it,” said Maria Cristina Aspesi, Lavazza Group Customer Care Director. “With SightCall, we have chosen a solution that gives both central and local customer care teams a single, cutting-edge tool to help customers and consumers, increasing the number of support and interaction cases that can be solved instantaneously.”
About SightCall
SightCall is the world’s leading augmented-reality powered video cloud platform, delivering live, remote interactions between business and customers on every continent around the globe. In a connected, mobile-first world, businesses leveraging SightCall have the ability to see what their customers see and guide them remotely. With nearly 15 years of experience in remote video assistance, SightCall helps businesses transform their customer service and field service with the power of augmented reality and live video. The company has offices in San Francisco (HQ), Austin, Boston, Frankfurt, London, Melbourne, Paris and Singapore. Visit sightcall.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005412/en/
Contact information
Katie Smart
katie.smart@sightcall.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
